目次

1. Research Methodology

2. Introduction To Orphan Drugs

3. Global Orphan Drug Designation Criteria
3.1 US
3.2 Europe
3.3 Asia and Australia

4. Market Exclusivity and Patent Protection for Orphan Drugs

5. Global Orphan Designated Cancer Drug Market
5.1 Current Market Scenario
5.2 Future Market Opportunity

6. Orphan Designated Cancer Drug Market Insight by Region
6.1 US
6.2 Europe
6.3 Japan
6.4 South Korea
6.5 China
6.6 Australia
6.7 UK
6.8 Canada
6.9 Middle East

7. Global Orphan Designated Cancer Drug Market by Indication
7.1 Lymphoma
7.2 Leukemia
7.3 Lung Cancer
7.4 Multiple Myeloma
7.5 Ovarian Cancer
7.6 Gastric Cancer
7.7 Thyroid Cancer
7.8 Liver Cancer
7.9 Pancreatic Cancer
7.10 Melanoma
7.11 Brain Cancer
7.12 Renal Cell Carcinoma

8. Top 50 Orphan Designated Cancer Drugs - Availability, Dosage, Price and Sales Forecats 2028

9. THIS CHAPTER GIVES COMPREHENISVE CLINICAL and COMMERCIAL INSIGHT ON TOP 50 ORPHAN DESIGNATED CANCER DRUGS. THESE DRUGS ACCOUNT FOR MORE THAN 70% OF TOTAL ORPHAN DESIGNATED CANCER DRUG MARKET.

10. Global Orphan Cancer Drugs Clinical Pipeline Overview
10.1 9.1 By Company
10.2 9.2 Drug Class
10.3 9.3 Indication
10.4 9.4 Priority Status
10.5 9.5 By Phase

11. Global Orphan Cancer Drugs Clinical Pipeline By Company, Country , Indication and Phase
11.1 10.1 Preclinical
11.2 10.2 Phase-I
11.3 10.3 Phase-I/II
11.4 10.4 Phase-II
11.5 10.5 Phase-II/III

12. 10.6 Phase-III

13. 10.7 Preregistration

14. 10.8 Registered

15. Marketed Orphan Cancer Drugs Clinical Insight By Company, Country and Indication

16. Competitive Landscape
16.1 12.1 AOP Orphan
16.2 12.2 Agenus
16.3 12.3 Alexion
16.4 12.4 Bristol Myers Squibb
16.5 12.5 Biogen Idec
16.6 12.6 Celgene
16.7 12.7 Eli Lilly
16.8 12.8 Genethon
16.9 12.9 Genzyme Corporation
16.10 12.10 Glaxosmithkline
16.11 12.11 Merck
16.12 12.12 Novartis Pharmaceuticals
16.13 12.13 Orphan Europe
16.14 12.14 Pfizer
16.15 12.15 Prosensa
16.16 12.16 Rare Disease Therapeutics
16.17 12.17 Roche
16.18 12.18 Sanofi
16.19 12.19 Shire
16.20 12.20 Teva Pharmaceutical

List of Figures & Tables
Figure 5-1: Global ? Rare vs. Other Cancer Prevalence (%) Figure 5-2: Global ? Top 10 Orphan Cancer Drug Sales (US$ Billion), 2021 Figure 5-3: Global ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 5-4: Orphan Cancer Drugs ? Sales Value by Region (US$ Billion), 2021 Figure 5-5: Orphan Cancer Drugs ? Sales Value by Region (%), 2021 Figure 5-6: Global ? Sales of Orphan Designated Cancer Drugs (US$ Billion), 2022 ? 2028 Figure 6-1: US ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-2: US vs. ROW ? Sales of Orphan Cancer Drugs (US$ Billion), 2021 Figure 6-3: US vs. ROW ? Sales of Orphan Cancer Drugs (%), 2021 Figure 6-4: US ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-5: Europe ? Orphan Drug Designation by Indication, 2021 Figure 6-6: Europe ? Orphan Drug Designation by Indication (%), 2021 Figure 6-7: Europe ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-8: Europe vs. ROW ? Sales of Orphan Cancer Drugs (US$ Billion), 2021 Figure 6-9: Europe vs. ROW ? Sales of Orphan Cancer Drugs (%), 2021 Figure 6-10: Europe ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-11: Japan ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-12: Japan vs. ROW ? Sales of Orphan Cancer Drugs (US$ Billion), 2021 Figure 6-13: Japan vs. ROW ? Sales of Orphan Cancer Drugs (%), 2021 Figure 6-14: Japan ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-15: South Korea ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-16: South Korea ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-17: China ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-18: China ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-19: Australia ? Average Incidences and Deaths of Rare Cancer Figure 6-20: Australia ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-21: Australia ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-22: UK ? Orphan Drug Designation by Indication, 2021 Figure 6-23: UK ? Orphan Drug Designation by Indication (%), 2021 Figure 6-24: UK ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-25: UK vs. ROW ? Sales of Orphan Cancer Drugs (US$ Billion), 2021 Figure 6-26: UK vs. ROW ? Sales of Orphan Cancer Drugs (%), 2021 Figure 6-27: UK ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-28: Canada ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-29: Canada ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 6-30: Middle East ? Sales of Orphan Cancer Drugs (US$ Billion), 2020 and 2021 Figure 6-31: Middle East ? Sales of Orphan Cancer Drugs (US$ Billion), 2022 - 2028 Figure 7-1: Global ? Sales of Orphan Designated Lymphoma Drugs (US$ Billion), 2021 - 2028 Figure 7-2: Global ? Sales of Leukemia Designated Orphan Drugs (US$ Billion), 2021 - 2028 Figure 7-3: Global ? Sales of Lung Cancer Designated Orphan Drugs (US$ Billion), 2021 - 2028 Figure 7-4: Global ? Sales of Multiple Myeloma Designated Orphan Drugs (US$ Billion), 2021 - 2028 Figure 7-5: Global ? Sales of Ovarian Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-6: Global ? Sales of Gastric Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-7: Global ? Sales of Thyroid Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-8: Global ? Sales of Liver Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-9: Global ? Sales of Pancreatic Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-10: Global ? Sales of Melanoma Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-11: Global ? Sales of Brain Cancer Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 7-12: Global ? Sales of Renal Cell Carcinoma Designated Orphan Drugs (US$ Million), 2021 - 2028 Figure 8-1: Rituxan ? FDA Approval Year by Indication Figure 8-2: Rituxan ? FDA Orphan Designation Year by Indication Figure 8-3: Rituxan ? Price for a Supply of 10 ml and Price Per ml of Injection (US$), June’2022 Figure 8-4: Rituxan ? Price for a Supply of 50 ml and Price Per ml for Injection (US$), June’2022 Figure 8-5: Rituxan ? Price for a Supply of 100 ml and Price Per ml for Injection (US$), June’2022 Figure 8-6: Rituxan Combination ? Average Minimum and Maximum Cost for Refractory CD20+ B-Cell NHL Management (US$), June’2022 Figure 8-7: Rituxan Combination ? Average Cost for Single Dose and Cost of Full Maintenance Phase for CLL (US$), June’2022 Figure 8-8: Rituxan ? Value by Region (US$/CHF Million), Q1’2022 Figure 8-9: Global - Rituxan Sales Value (US$/CHF Million), 2018 - 2021 Figure 8-10: US - Rituxan Sales Value (US$/CHF Million), 2018 - 2021 Figure 8-11: Europe - Rituxan Sales Value (US$/CHF Million), 2018 - 2021 Figure 8-12: Japan - Rituxan Sales Value (US$/CHF Million), 2018 - 2021 Figure 8-13: ROW - Rituxan Sales Value (US$/CHF Million), 2018 - 2021 Figure 8-14: Rituxan - Sales Value by Region (US$/CHF Million), 2021 Figure 8-15: Rituxan - Sales Value by Region (%), 2021 Figure 8-16: Global - Rituximab Quarterly Sales Value (US$ Billion), 2021 Figure 8-17: Global - Rituxan Quarterly Sales Value (US$ Million), 2020 Figure 8-18: Global - Rituxan Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-19: US - Rituxan Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-20: Yervoy ? US and Europe Exclusivity Expiration Year Figure 8-21: Yervoy ? FDA Orphan Designation Year by Indication Figure 8-22: Yervoy - Price for 10ml Supply and Price Per ml of 5mg/ml Intravenous Injection (US$), June’2022 Figure 8-23: Yervoy ? Price for 40ml Supply and Price Per ml 5mg/ml Intravenous Injection (US$), June’2022 Figure 8-24: Yervoy ? Duration of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (Weeks), June’2022 Figure 8-25: Yervoy ? Average Cost of Single Treatment Cycle and Full Treatment of Metastatic Melanoma and Hepatocellular Carcinoma (US$), June’2022 Figure 8-26: Yervoy ? Average Cost of Single Treatment Cycle, Initial Year and Remaining Years for Management of Metastatic Melanoma (US$), June’2022 Figure 8-27: Global - Yervoy Sales Value by Region (US$ Million), Q1’2022 Figure 8-28: Global - Yervoy Sales Value by Region (%), Q1’2022 Figure 8-29: Yervoy ? Sales Value (US$ Billion), 2016-2021 Figure 8-30: Yervoy ? Sales by Region (US$ Million), 2021 Figure 8-31: Yervoy ? Sales by Region (US$ Million), 2021 Figure 8-32: Global - Yervoy Quarterly Sales Value (US$ Million), 2021 Figure 8-33: US - Yervoy Quarterly Sales Value (US$ Million), 2021 Figure 8-34: Global - Yervoy Quarterly Sales Value (US$ Million), 2020 Figure 8-35: Yervoy ? Quarterly Sales Value (US$ Million), 2018 and 2019 Figure 8-36: US - Yervoy Quarterly Sales Value (US$ Million), 2019 Figure 8-37: Yervoy ? US v/s Rest of World Sales Share (%), 2019 Figure 8-38: Global - Yervoy Sales Forecast (US$ Million), 2022 - 2028 Figure 8-39: US - Yervoy Sales Forecast (US$ Million), 2022 - 2028 Figure 8-40: Opdivo - Patent Expiration Year by Region Figure 8-41: Opdivo ? US FDA Orphan Designation Year by Indication Figure 8-42: Opdivo - Price for 4ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022 Figure 8-43: Opdivo - Price for 10 ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022 Figure 8-44: Opdivo - Price for 12 ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022 Figure 8-45: Opdivo - Price for 24 ml Supply and Price Per ml of 10mg/ml Intravenous Injection (US$), June’2022 Figure 8-46: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), June’2022 Figure 8-47: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022 Figure 8-48: Global - Opdivo Sales Value by Region (%), Q1’2022 Figure 8-49: Global - Opdivo Sales Value (US$ Million), 2016 - 2021 Figure 8-50: US - Opdivo Sales Value (US$ Million), 2016 - 2021 Figure 8-51: Opdivo ? Sales by Region (US$ Million), 2021 Figure 8-52: Opdivo ? Sales by Region (US$ Million), 2021 Figure 8-53: Global - Opdivo Quarterly Sales Value (US$ Million), 2021 Figure 8-54: US - Opdivo Quarterly Sales Value (US$ Million), 2021 Figure 8-55: Global - Opdivo Quarterly Sales Value (US$ Million), 2020 Figure 8-56: US - Opdivo Quarterly Sales Value (US$ Million), 2020 Figure 8-57: Global ? Opdivo Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-58: US ? Opdivo Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-59: Kyprolis ? Proteolix Inc’s Patents Issue and Expiration Year Figure 8-60: Kyprolis ? Cydex Pharmaceutical’s Patent Issue and Expiration Year Figure 8-61: Kyprolis ? Issue and Expiration Year of Patents Assigned to Onyx Therapeutics Figure 8-62: Kyprolis ? Price of 10mg, 30mg and 60mg Intraveneous Powder for Injection (US$), June’2022 Figure 8-63: Kyprolis ? Initial Dose and Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week) Figure 8-64: Kyprolis - Initial Dose and Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Twice a Week) Figure 8-65: Kyprolis ? Sales by Region (US$ Million), Q1’2022 Figure 8-66: Kyprolis ? Sales by Region (US$ Million), Q1’2022 Figure 8-67: Kyprolis ? Sales Value (US$ Million), 2018 - 2021 Figure 8-68: Kyprolis ? Sales by Region (US$ Million), 2021 Figure 8-69: Kyprolis ? Sales by Region (US$ Million), 2021 Figure 8-70: Global - Kyprolis Quarterly Sales Value (US$ Million), 2021 Figure 8-71: US - Kyprolis Quarterly Sales Value (US$ Million), 2021 Figure 8-72: Global - Kyprolis Quarterly Sales Value (US$ Million), 2020 Figure 8-73: US - Kyprolis Quarterly Sales Value (US$ Million), 2020 Figure 8-74: Global ? Kyprolis Sales Forecast (US$ Million), 2022 - 2028 Figure 8-75: US - Kyprolis Sales Forecast (US$ Million), 2022 - 2028 Figure 8-76: Revlimid ? FDA Approval Year by Indication Figure 8-77: Revlimid ? FDA Approval and Patent Expiration Year Figure 8-78: Revlimid ? FDA Orphan Designation Year by Indication Figure 8-79: Revlimid ? Price for 28 capsules and 100 Capsules of 2.5mg, 5mg and 10mg Capsules (US$), June’2022 Figure 8-80: Revlimid ? Price for 21 capsules and 100 Capsules of 15mg, 20mg and 25mg Capsules (US$), June’2022 Figure 8-81: Revlimid ? Recommended Daily Dose by Indications (mg) Figure 8-82: Revlimid ? Sales by Region (US$ Million), Q1’2022 Figure 8-83: Revlimid ? Sales by Region (US$ Million), Q1’2022 Figure 8-84: Global ? Revlimid Sales Value (US$ Million), 2017 - 2021 Figure 8-85: US ? Revlimid Sales Value (US$ Million), 2017 - 2021 Figure 8-86: Revlimid ? Sales by Region (US$ Million), 2021 Figure 8-87: Revlimid ? Sales by Region (US$ Million), 2021 Figure 8-88: Global - Revlimid Quarterly Sales Value (US$ Million), 2021 Figure 8-89: US - Revlimid Quarterly Sales Value (US$ Million), 2021 Figure 8-90: Global - Revlimid Quarterly Sales Value (US$ Million), 2020 Figure 8-91: US - Revlimid Quarterly Sales Value (US$ Million), 2020 Figure 8-92: Global ? Revlimid Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-93: US ? Revlimid Sales Forecast (US$ Million), 2022 - 2028 Figure 8-94: Velcade ? FDA Approval Year by Indication Figure 8-95: Velcade ? Patent Issue and Expiration Year Figure 8-96: Velcade ? US FDA Orphan Designation Year by Indication Figure 8-97: Bortezomib ? Generic Approval By Companies Figure 8-98: Velcade ? Minimum and Maximum Cost of Single Treatment Cycle (US$), June’2022 Figure 8-99: Velcade ? Minimum and Maximum Cost of Single Treatment Cycle (US$), June’2022 Figure 8-100: Global ? Velcade Sales Value (JPY/US$ Billion), 2017 - 2021 Figure 8-101: Global ? Velcade Quarterly Sales Value (JPY/US$ Billion), Q1-Q3’2021 Figure 8-102: US ? Velcade Sales Value (JPY/US$ Billion), 2018 - 2021 Figure 8-103: Global ? Velcade Sales Value by Region (%), 2020 Figure 8-104: Global ? Velcade Sales Forecast (US$ Million), 2022 - 2028 Figure 8-105: US ? Velcade Sales Forecast (US$ Million), 2021-2026 Figure 8-106: Pomalyst ? FDA Approval and Patent Expiration Year Figure 8-107: Pomalyst ? US FDA Orphan Designation Year by Indication Figure 8-108: Pomalyst ? Orphan Designation Year by Region Figure 8-109: Pomalyst ? Price for 21 Capsules Supply and Price per unit Capsule of Various Dose Regimens (US$), June’2022 Figure 8-110: Pomalyst ? Price for 100 Capsules Supply and Price per unit Capsule of Various Dose Regimens (US$), June’2022 Figure 8-111: Pomalyst ? Recommended Initial and Reduced Dose (mg/day) Figure 8-112: Pomalyst ? Sales by Region (US$ Million), Q1’2022 Figure 8-113: Pomalyst ? Sales by Region (US$ Million), Q1’2022 Figure 8-114: Global - Pomalyst Sales Value (US$ Million), 2017 - 2021 Figure 8-115: Pomalyst ? Sales by Region (US$ Million), 2021 Figure 8-116: Pomalyst ? Sales by Region (US$ Million), 2021 Figure 8-117: Pomalyst ? US v/s Rest of World Sales Value (US$ Million), 2020 Figure 8-118: Pomalyst ? US v/s Rest of World Sales Value (%), 2020 Figure 8-119: Global - Pomalyst Quarterly Sales Value (US$ Million), 2021 Figure 8-120: US - Pomalyst Quarterly Sales Value (US$ Million), 2021 Figure 8-121: Global - Pomalyst Quarterly Sales Value (US$ Million), 2020 Figure 8-122: US - Pomalyst Quarterly Sales Value (US$ Million), 2020 Figure 8-123: Global ? Pomalyst Sales Forecast (US$ Million), 2022 - 2028 Figure 8-124: US ? Pomalyst Sales Forecast (US$ Million), 2022 - 2028 Figure 8-125: Sprycel ? FDA Approval Year by Tablet Strength Figure 8-126: Sprycel ? Patent Issue and Expiration Year Figure 8-127: Sprycel ? US FDA Orphan Designation Issue and Exclusivity Expiration Year Figure 8-128: Sprycel ? Price for 60 Tablets and Price per Unit Tablet of 20mg, 50mg and 70mg (US$), June’2022 Figure 8-129: Sprycel ? Price for 30 Tablets and Price per Unit Tablet of 80mg, 100mg and 140mg (US$), June’2022 Figure 8-130: Sprycel ? Recommended Dose by Indication (mg/day) Figure 8-131: Sprycel ? Recommended Pediatric Dose by Weight (mg/day) Figure 8-132: Sprycel ? Sales by Region (US$ Million), Q1’2022 Figure 8-133: Sprycel ? Sales by Region (US$ Million), Q1’2022 Figure 8-134: Global - Sprycel Sales Value (US$ Million), 2018 - 2021 Figure 8-135: US - Sprycel Sales Value (US$ Million), 2018 - 2021 Figure 8-136: Sprycel ? Sales by Region (US$ Million), 2021 Figure 8-137: Sprycel ? Sales by Region (US$ Million), 2021 Figure 8-138: Sprycel ? US v/s Rest of World Sales Value (US$ Million), 2020 Figure 8-139: Sprycel ? US v/s Rest of World Sales Value (%), 2020 Figure 8-140: Global - Sprycel Quarterly Sales Value (US$ Million), 2021 Figure 8-141: US - Sprycel Quarterly Sales Value (US$ Million), 2021 Figure 8-142: Global - Sprycel Quarterly Sales Value (US$ Million), 2020 Figure 8-143: Global ? Sprycel Sales Forecast (US$ Million), 2022 - 2028 Figure 8-144: US ? Sprycel Sales Forecast (US$ Million), 2022 - 2028 Figure 8-145: Imbruvica ? FDA Approval Year by Indication Figure 8-146: Imbruvica ? FDA Orphan Designation Year by Indication Figure 8-147: Imbruvica ? FDA Approval Year by Dosage Form Figure 8-148: Imbruvica ? Approval Year by Region Figure 8-149: Ibrutinib ? Patent and Exclusivity Expiration Year Figure 8-150: Imbruvica ? Price for 90 and 120 Capsule Supplies of 140mg (US$), June’2022 Figure 8-151: Imbruvica Capsule ? Price for 28 Capsule and Price Per unit Capsule of 70mg (US$), June’2022 Figure 8-152: Imbruvica Tablet ? Price for 28 Tablets and Price Per unit Tablet of Various Doses (US$), June’2022 Figure 8-153: Imbruvica ? Recommended Daily Dose by Indication (mg) Figure 8-154: Imbruvica - Sales Value by Region (US$ Million), Q1’2022 Figure 8-155: Imbruvica ? Sales Value by Region (%), Q1’2022 Figure 8-156: Imbruvica ?Sales Value (US$ Billion), 2017 - 2021 Figure 8-157: Imbruvica - Sales Value by Region (US$ Million), 2021 Figure 8-158: Imbruvica ? Sales Value by Region (%), 2021 Figure 8-159: Global - Imbruvica Quarterly Sales Value (US$ Million), 2021 Figure 8-160: US - Imbruvica Sales Value (US$ Billion), 2017 - 2021 Figure 8-161: US - Imbruvica Quarterly Sales Value (US$ Million), 2021 Figure 8-162: Global ? Imbruvica Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-163: US ? Imbruvica Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-164: Alimta ? US FDA Approval and Orphan Designation Figure 8-165: Alimta ? FDA Approval Year by Dose Regimen Figure 8-166: Alimta ? Patent Issue and Expiration Year Figure 8-167: Alimta ? Price for 100mg and 500mg Intravenous Powder (US$), June’2022 Figure 8-168: Alimta ? Treatment Cycle required in Combination with Pembrolizumab v/s Cisplatin Figure 8-169: Alimta ? Cost of Single Treatment Cycle and Full Treatment Cost of NSCLC (US$), June’2022 Figure 8-170: Alimta ? US v/s Rest of World Sales Value (US$ Million), Q1’2022 Figure 8-171: Alimta ? US v/s Rest of World Sales Value (%), Q1’2022 Figure 8-172: Global - Alimta Sales Value (US$ Billion), 2016 - 2021 Figure 8-173: Alimta ? US v/s Rest of World Sales Value (US$ Million), 2021 Figure 8-174: Alimta ? US v/s Rest of World Sales Value (%), 2021 Figure 8-175: Alimta ? US v/s Rest of World Sales Value (US$ Million), 2020 Figure 8-176: Alimta ? US v/s Rest of World Sales Value (%), 2020 Figure 8-177: Global - Alimta Quarterly Sales Value (US$ Million), 2021 Figure 8-178: US - Alimta Quarterly Sales Value (US$ Million), 2021 Figure 8-179: Global - Alimta Quarterly Sales Value (US$ Million), 2020 Figure 8-180: US - Alimta Quarterly Sales Value (US$ Million), 2020 Figure 8-181: Global ? Alimta Sales Forecast (US$ Million), 2022 - 2028 Figure 8-182: US ? Alimta Sales Forecast (US$ Million), 2022 - 2028 Figure 8-183: Tasigna ? FDA Approval Year by Indication Figure 8-184: Tasigna ? Patent Issue and Expiration Year Figure 8-185: Tasigna ? Price for 120 Capsules and Price per unit Capsule of 50mg (US$), June’2022 Figure 8-186: Tasigna ? Price for 28 Capsules and Price per unit Capsule of 150mg and 200mg (US$), June’2022 Figure 8-187: Tasigna ? Price for 112 Capsules and Price per unit Capsule of 150mg and 200mg (US$), June’2022 Figure 8-188: Tasigna ? Recommended Dose by Indication (mg Twice Daily) Figure 8-189: Tasigna ? Recommended Pediatric Dose by Surface Area (mg Twice Daily) Figure 8-190: Global - Tasigna Quarterly Sales Value (US$ Million), Q1’2022 and Q1’2021 Figure 8-191: Global - Tasigna Sales Value (US$ Million), 2017 - 2021 Figure 8-192: Global - Tasigna Quarterly Sales Value (US$ Million), 2021 Figure 8-193: Global - Tasigna Quarterly Sales Value (US$ Million), 2020 Figure 8-194: Global ? Tasigna Sales Forecast (US$ Million), 2022 - 2028 Figure 8-195: Keytruda ? Patent Expiration Year by Region Figure 8-196: Keytruda ? US FDA Orphan Designation Year by Indication Figure 8-197: US - Price for 4ml, 8ml Supply and Price Per ml of Keytruda Intravenous Injection (US$), June’2022 Figure 8-198: Keytruda ? Duration of Single Treatment Cycle and Full Treatment of Melanoma and Other Cancers (Weeks) Figure 8-199: Keytruda - Cost of Single and Full Treatment using Solution of Injection (US$), June’2022 Figure 8-200: Global - Keytruda Sales Value (US$ Million), Q1’2021 and Q1’2022 Figure 8-201: Global - Keytruda Sales Value (US$ Billion), 2018 - 2021 Figure 8-202: Global - Keytruda Quarterly Sales Value (US$ Billion), 2021 Figure 8-203: Global - Keytruda Quarterly Sales Value (US$ Billion), 2020 Figure 8-204: Global ? Keytruda Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-205: Avastin ? Orphan Designation Year by Region Figure 8-206: Avastin ? US FDA Orphan Designation Year by Indication Figure 8-207: Avastin ? Price for a Supply of 10 and Price for Single 4ml Solution for Injection (US$), June’2022 Figure 8-208: Avastin ? Price for a Supply of 10 and Price for Single 16ml Solution for Injection (US$), June’2022 Figure 8-209: Avastin ? Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), June’2022 Figure 8-210: Avastin ? Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), June’2022 Figure 8-211: Avastin ? Duration of Treatment of Recurrent Glioblastoma and Renal Cell Carcinoma as Combinational and Monotherapy (Weeks) Figure 8-212: Avastin ? Cost of Single Treatment Cycle and Annual Treatment Cost for Recurrent Glioblastoma and Renal Cell Carcinoma (US$), June’2022 Figure 8-213: Avastin ? Sales Value by Region (US$/CHF Million), Q1’2022 Figure 8-214: Avastin ? Sales Value by Region (%), Q1’2022 Figure 8-215: Global - Avastin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-216: US - Avastin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-217: Europe - Avastin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-218: Japan - Avastin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-219: ROW - Avastin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-220: Avastin - Sales Value by Region (US$/CHF Million), 2021 Figure 8-221: Avastin - Sales Value by Region (%), 2021 Figure 8-222: Global - Avastin Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-223: US - Avastin Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-224: Global ? Avastin Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-225: Tagrisso - Patent Issue and Expiration Year Figure 8-226: Tagrisso - Price for 30 Tablet Supply and Price per unit of 200 mg Oral Tablet (US$), June’2022 Figure 8-227: Tagrisso - Recommended and Reduced Dose for NSCLC Treatment (mg per day) Figure 8-228: Tagrisso - Sales Value by Region (US$ Million), Q1’2022 Figure 8-229: Tagrisso ? Sales Value by Region (%), Q1’2022 Figure 8-230: Tagrisso ? Sales Value (US$ Million), 2017 - 2021 Figure 8-231: Tagrisso - Sales Value by Region (US$ Million), 2021 Figure 8-232: Tagrisso ? Sales Value by Region (%), 2021 Figure 8-233: Tagrisso - Sales Value by Region (US$ Million), 2020 Figure 8-234: Tagrisso ? Sales Value by Region (%), 2020 Figure 8-235: Global - Tagrisso Quarterly Sales Value (US$ Million), 2021 Figure 8-236: Global - Tagrisso Quarterly Sales Value (US$ Million), 2020 Figure 8-237: Global ? Tagriso Sales Forecast (US$ Million), 2022 - 2028 Figure 8-238: US ? Tagriso Sales Forecast (US$ Million), 2022 - 2028 Figure 8-239: Europe ? Tagriso Sales Forecast (US$ Million), 2022 - 2028 Figure 8-240: Herceptin ? Approval Year by Cancer Type Figure 8-241: Herceptin ? Orphan Designation Year by Indication Figure 8-242: Herceptin ? Price for a Supply of 10 and Price for Single 150mg Powder for Injection (US$), June’2022 Figure 8-243: Herceptin ? Initial and Maintenance Dose for Breast Cancer Treatment (mg/kg) Figure 8-244: Herceptin ? Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Breast Cancer (US$), March’2022 Figure 8-245: Herceptin ? Initial and Maintenance Dose for Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (mg/kg) Figure 8-246: Herceptin ? Cost of Initial Dose, Maintenance Dose and Annual Treatment Cost of Adjuvant Breast Cancer, Gastric and Esophageal Carcinoma (US$), March’2022 Figure 8-247: Herceptin ? Sales Value by Region (US$/CHF Million), Q1’2022 Figure 8-248: Herceptin ? Sales Value by Region (%), Q1’2022 Figure 8-249: Global - Herceptin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-250: US - Herceptin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-251: Europe - Herceptin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-252: Japan - Herceptin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-253: ROW - Herceptin Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-254: Herceptin - Sales Value by Region (US$/CHF Million), 2021 Figure 8-255: Herceptin - Sales Value by Region (%), 2021 Figure 8-256: Global - Herceptin Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-257: US - Herceptin Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-258: Global ? Hercepin Sales Forecast (US$ Million), 2022 - 2028 Figure 8-259: Darzalex ? FDA Approval and Patent Expiration Year Figure 8-260: Darzalex ? FDA Orphan Designation Year by Indication Figure 8-261: Darzalex ? EMA Orphan Designation Year by Indication Figure 8-262: Darzalex ? Price for 5 ml Supply and Price per ml of 20mg/ml Intravenous Solution (US$), June’2022 Figure 8-263: Darzalex ? Price for 20 ml Supply and Price per ml of 20mg/ml Intravenous Solution (US$), June’2022 Figure 8-264: Darzalex ? Duration of Dose Interval by Treatment Phase (Weeks) Figure 8-265: Darzalex - Sales Value by Region (US$ Million), Q1’2022 Figure 8-266: Darzalex ? Sales Value by Region (%), Q1’2022 Figure 8-267: Global - Darzalex Sales Value (US$ Million), 2017 - 2021 Figure 8-268: US - Darzalex Sales Value (US$ Million), 2017 - 2021 Figure 8-269: Darzalex - Sales Value by Region (US$ Million), 2021 Figure 8-270: Darzalex ? Sales Value by Region (%), 2021 Figure 8-271: Darzalex ? Sales by Region (%), 2019 Figure 8-272: Darzalex ? Sales Value by Region (%), 2020 Figure 8-273: Global - Darzalex Quarterly Sales Value (US$ Million), 2021 Figure 8-274: US - Darzalex Quarterly Sales Value (US$ Million), 2021 Figure 8-275: Global - Darzalex Quarterly Sales Value (US$ Million), 2020 Figure 8-276: US - Darzalex Quarterly Sales Value (US$ Million), 2019 Figure 8-277: US - Darzalex Quarterly Sales Value (US$ Million), 2020 Figure 8-278: Global ? Darzalex Sales Forecast (US$ Billion), 2022 - 2028 Figure 8-279: US ? Darzalex Sales Forecast (US$ Million), 2022 - 2028 Figure 8-280: Venclexta ? Approval Year by Region Figure 8-281: Venclexta ? FDA Approval Year by Indication Figure 8-282: Venclexta ? FDA Orphan Designation Year by Indication Figure 8-283: Venclexta ? Orphan Designation Year by Region Figure 8-284: Venetoclax - Patent Issue and Expiration year Figure 8-285: Venclexta ? Price for 2 Tablet Supply and Price per unit Tablet of 10mg (US$), June’2022 Figure 8-286: Venclexta ? Price for 14 Tablet Supply and Price per unit Tablet of 10mg (US$), June’2022 Figure 8-287: Venclexta ? Price for Various Supplies of 50mg Tablet (US$), June’2022 Figure 8-288: Venclexta ? Price for 120 Tablet Supply and Price per unit Tablet of 100mg (US$), June’2022 Figure 8-289: Venclexta ? Price for 180 Tablet Supply and Price per unit Tablet of 100mg (US$), June’2022 Figure 8-290: Venclexta ? Price for 42 Kit and Price per unit Kit (US$), June’2022 Figure 8-291: Venetoclax Monotherapy ? Recommended Dose by Treatment Week for CLL Management (mg/day) Figure 8-292: Venetoclax Combinational ? Recommended Dose in Initial and Subsequent Treatment Cycle for CLL (mg/Cycle) Figure 8-293: Venetoclax Monotherapy ? Recommended Dose for AML (mg/day) Figure 8-294: Venclexta - Sales Value by Region (US$ Million), Q1’2022 Figure 8-295: Venclexta ? Sales Value by Region (%), Q1’2022 Figure 8-296: Global - Venclexta Sales Value (US$ Million), 2018 - 2021 Figure 8-297: US - Venclexta Sales Value (US$ Million), 2018 - 2021 Figure 8-298: Venclexta - Sales Value by Region (US$ Million), 2021 Figure 8-299: Venclexta ? Sales Value by Region (%), 2021 Figure 8-300: Venclexta - Sales Value by Region (US$ Million), 2020 Figure 8-301: Venclexta ? Sales Value by Region (%), 2020 Figure 8-302: Global - Venclexta Quarterly Sales Value (US$ Million), 2021 Figure 8-303: US - Venclexta Quarterly Sales Value (US$ Million), 2021 Figure 8-304: Global - Venclexta Quarterly Sales Value (US$ Million), 2020 Figure 8-305: US - Venclexta Quarterly Sales Value (US$ Million), 2020 Figure 8-306: Global ? Venclexta Sales Forecast (US$ Million), 2022 - 2028 Figure 8-307: US ? Venclexta Sales Forecast (US$ Million), 2022 - 2028 Figure 8-308: Tecentriq ? FDA Approval and Patent Expiration Year Figure 8-309: Tecentriq ? FDA Orphan Designation Year by Indication Figure 8-310: Tecentriq - Price for 14ml Supply and Price Per ml of 840mg/14ml Intravenous Injection (US$), June’2022 Figure 8-311: Tecentriq - Price for 20ml Supply and Price Per ml of 1200mg/20ml Intravenous Injection (US$), June’2022 Figure 8-312: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), June’2022 Figure 8-313: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), June’2022 Figure 8-314: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), June’2022 Figure 8-315: Tecentriq ? Sales Value by Region (US$/CHF Million), Q1’2022 Figure 8-316: Tecentriq ? Sales Value by Region (%), Q1’2022 Figure 8-317: Global - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-318: US - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-319: Europe - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-320: Japan - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-321: ROW - Tecentriq Sales Value (US$/CHF Million), 2019 - 2021 Figure 8-322: Tecentriq - Sales Value by Region (US$/CHF Million), 2021 Figure 8-323: Tecentriq - Sales Value by Region (%), 2021 Figure 8-324: Global - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-325: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2021 Figure 8-326: US - Tecentriq Quarterly Sales Value (US$/CHF Million), 2020 Figure 8-327: Global ? Tecentriq Sales Forecast (US$ Million), 2022 - 2028 Figure 8-328: US ? Tecentriq Sales Forecast (US$ Million), 2022 - 2028 Figure 8-329: Europe ? Tecentriq Sales Forecast (US$ Million), 2022 - 2028 Figure 8-330: Japan ? Tecentriq Sales Forecast (US$ Million), 2022 - 2028 Figure 8-331: ROW ? Tecentriq Sales Forecast (US$ Million), 2022 - 2028 Figure 8-332: Kadcyla ? FDA Approval Year for Late Stage and Early Stage HER2+ Breast Cancer Figure 8-333: Kadcyla ? Patent Expiration Year by Region Figure 8-334: US - Price for Single Unit of Kadcyla 100